Long-Term Safety Evaluation of Dupilumab in Patients With Asthma (LIBERTY ASTHMA TRAVERSE)
Status:
Completed
Trial end date:
2019-10-11
Target enrollment:
Participant gender:
Summary
Primary Objective:
To evaluate the long-term safety and tolerability of dupilumab in participants with asthma
who participated in a previous dupilumab asthma study (DRI12544, PDY14192, EFC13579,
EFC13691).
Secondary Objectives:
To evaluate the long-term efficacy of dupilumab in participants with asthma who participated
in a previous dupilumab asthma clinical study.
To evaluate dupilumab in participants with asthma who participated in a previous dupilumab
asthma clinical study, with regards to:
- Systemic exposure
- Anti-drug antibodies
- Biomarkers